Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 22;2019:3947245.
doi: 10.1155/2019/3947245. eCollection 2019.

Zika Virus Targeting by Screening Inhibitors Against NS2B/NS3 Protease

Affiliations
Free PMC article

Zika Virus Targeting by Screening Inhibitors Against NS2B/NS3 Protease

Hani Choudhry et al. Biomed Res Int. .
Free PMC article

Abstract

Zika flavivirus is suspected to cause Guillain-Barre syndrome in adults and microcephaly, along with other congenital abnormalities in infants. Presently, no vaccines or therapeutics are available. Here, we report novel compounds identified by high-throughput virtual screening of Maybridge chemical database and molecular docking studies. We selected viral enzyme NS2B/NS3 serine protease as the therapeutic target because of its important role in viral replication. We selected seven potential compounds as antiviral drug candidates because of their high GOLD fitness score, high AutoDock Vina score, or X-Score binding energy and analyzed the strength of molecular interactions between the active site amino acids and selected compounds. Our study also provides a foundation for similar studies for the search of novel therapeutics against Zika virus.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Binding mode of boronate inhibitor (positive control as reference) at the active site of NS3.
Figure 2
Figure 2
Figure represents 2D structures of the seven best-selected compounds.
Figure 3
Figure 3
Figure represents the conformation of ligands (selected compounds) at the active site of target NS2B/NS3 serine protease. (a) CD03173. (b) CD11575. (c) HTS03171. (d) HTS04601. (e) HTS07252. (f) JFD01698. (g) KM10383.

Similar articles

See all similar articles

References

    1. Faye O., Faye O., Dupressoir A., et al. One step RT-PCR for detection of Zikavirus. Journal of Clinical Virology. 2008;43(1):96–101. doi: 10.1016/j.jcv.2008.05.005. - DOI - PubMed
    1. Duong V., Dussart P., Buchy P. Zikavirus in Asia. International Journal of Infectious Diseases. 2017;54:121–128. doi: 10.1016/j.ijid.2016.11.420. - DOI - PubMed
    1. Poland G. A., Kennedy R. B., Ovsyannikova I. G., et al. Development of vaccines against Zika virus. The Lancet Infectious Diseases. 2018;18(7):e211–e219. doi: 10.1016/s1473-3099(18)30063-x. - DOI - PubMed
    1. Dick G. W., Kitchen S. F., Haddow A. J. Zika virus. I. Isolations and serological specificity. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1952;46(5):509–520. doi: 10.1016/0035-9203(52)90042-4. - DOI - PubMed
    1. Fagbami A. H. Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State. Journal of Hygiene. 1979;83(2):213–219. doi: 10.1017/s0022172400025997. - DOI - PMC - PubMed

MeSH terms

Feedback